An observational study in Melanoma (Skin Cancer), sponsored by European Institute of Oncology. Recruiting at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by European Institute of Oncology · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 268 studies in Melanoma with a site in Italy — 47 open to participants now, 81 under way, 22 of them phase 3. Melanoma · Italy.
Among the 268 studies in Melanoma with a site in Italy, this one is the 27th largest by planned enrollment of the 31 observational ones that give a count, is one of 5 that started in 2026, is one of 31 observational ones, reaches primary completion later than 73 of the 80 other live ones, and was the 265th registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →47 of the 268 studies in Melanoma with a site in Italy are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Italy, United States, Belgium and 10 more countries
Ages 18+
IDEAYA Biosciences · Sites in Italy, United States, Australia and 18 more countries
Ages 18+
mAbxience Research S.L. · Sites in Italy, Bosnia and Herzegovina, Brazil and 10 more countries
Ages 18+
Ente Ospedaliero Ospedali Galliera · Sites in Italy
Ages 18–39
Melanoma Institute Australia · Sites in Italy, United States, Australia and 3 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
268 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 65 · Phase 2 106 · Phase 3 79 · Phase 4 1
First in 1995; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 187 across 489 observational studies indexed under Melanoma.
Median enrollment 191 across the 236 interventional studies, 270 across the 31 observational. Of the 165 that completed or were terminated, 92 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
191 of 268 have an industry lead sponsor. The 10 most frequent:
European Institute of Oncology is the lead sponsor of 185 studies on the registry; 118 are open to participants now.
European Institute of Oncology has 9 studies filed under Melanoma — fewer than ten, so there is no comparison to draw.
26 of the studies in Melanoma with a site in Italy that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05608291Phase 3Regeneron PharmaceuticalsA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | 2027-01-15 |
| NCT05987332Phase 3IDEAYA BiosciencesIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | 2027-01-15 |
| NCT05270044Phase 3Pierre Fabre MedicamentAdjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. | 2027-03-31 |
| NCT07221734Phase 3mAbxience Research S.L.Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma | 2027-04 |
| NCT05522660Phase 3ETOP IBCSG Partners FoundationImmunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer | 2027-06 |
Add all 26 to your calendar (.ics) → With an account.
Among the 268 studies in Melanoma with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Melanoma is a type of cancer that can spread to the brain, making the disease harder to treat and worsening both survival and quality of life.
In recent years, treatments have improved significantly thanks to advances in surgery, radiotherapy, immunotherapy, and targeted therapy. These new treatments have greatly increased survival rates for patients with metastatic melanoma.
This study focuses on stereotactic radiosurgery, a highly precise form of radiotherapy used to treat brain metastases. Researchers want to better understand how this treatment works when combined with immunotherapy or targeted therapy, and whether the timing and sequence of treatments can improve outcomes.
Between 2026 and 2028, patients treated at the IEO for melanoma brain metastases will be observed and their clinical data collected. The goal is to improve future treatment strategies and help doctors choose the best therapeutic approach for each patient.
The therapeutic landscape of metastatic melanoma has undergone a radical transformation in the last decade, largely due to the recent introduction of immune checkpoint inhibitors (IT) and targeted therapies (TTs), and advances in surgery and radiotherapy (RT), which have changed the outlook of patients with melanoma brain metastasis.
Radiation therapy has been and remains an important component of treatment for patients with melanoma brain metastases.
Particularly, stereotactic radiosurgery (SRS), highly precise RT technique, for single or a small number of metastases, has emerged as a crucial component in the management of melanoma brain metastases, with whole brain RT usually reserved for selected patients who have widespread intracranial metastatic disease. SRS relies on the delivery of concentrated, high doses of radiation to one or more metastatic brain lesions of otherwise radio-resistant tumors such as melanoma, providing effective local control (LC) of the disease while minimizing damage to surrounding healthy tissue. SRS can be employed both as an independent primary local therapy, allowing a swifter transition to systemic therapy compared to classic surgical resection and as a salvage procedure after ineffective systemic treatment when the number of MBMs remains below 5-10 and their size is below 3 cm.
A recent systematic review of RT alone for MBMs reported a median survival of 7.5 months (IQR-6.7-9.0-months) after SRS and 3.5 months (IQR-2.4-4.0-months) after whole brain RT.
Although these advances have successfully improved the outcomes of patients with metastatic melanoma, its management remains challenging and complex, requiring a multidisciplinary approach that integrates surgery, systemic therapy, and RT to optimize patient outcomes.
Ongoing investigations in this field are now focused on determining the best strategies to combine RT modalities with systemic therapies (IT and TT), emphasizing the potential for synergistic effects that enhance treatment efficacy. However, data on optimal sequencing and toxicity management, particularly in the context of radiosurgery, remain limited and require careful evaluation. The approach of combining RT with IT or TT has therefore become established in practice but this strategy has not been evaluated in randomized controlled trials. Clinical guidelines vary in the strength of their recommendations for combining different treatments. Studies differ in terms of patient selection, the extent of extracranial disease, the number of lesions treated, and the definitions of concurrent versus non-concurrent therapies. These differences make it challenging to draw definitive conclusions about the optimal treatment strategy for melanoma brain metastases.
In this prospective observational study, the investigators aim to analyse the impact of RT in a well selected population of patient receiving SRS at the European Institute of Oncology- IRCCS- Milan- as first local approach for MBMs, in combination with different type and timing of systemic treatment.
By analysing data from patients treated with CyberKnife from 2026 to 2028, the investigatorsseek to provide insights into the effectiveness of SRS according LC, overall survival (OS) and progression-free survival (PFS) in this patient population.
The investigators aim to investigate also potential prognostic factors including demographic, clinical, and therapeutic factors, with a focus on the influence of concurrent versus non-concurrent systemic therapies.
Through this prospective observational study, the investigators aim both to contribute to the growing body of evidence supporting the use of SRS as a viable treatment option for patients with MBMs and to identify factors that may enhance treatment efficacy and improve patient outcomes.
Patients receiving stereotactic radiotherapy for melanoma brain metastases as first local approach.
Target therapy and immunotherapy in combination or not will be permitted.
Given the descriptive nature of the study, no formal sample size calculation was performed. The planned sample size was predefined according to historical data from the RT Division and reflects the expected number of eligible patients treated at our institution over the planned three-year study period. Based on these data, we anticipate enrolling approximately 50 patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive stereotactic radiotherapy as first local approach for melanoma brain metastases in combination with target therapy and/or immunotherapy. Patients will be followed every three months after the end of radiotherapy in order to collect oncological outcome, side effects and Quality of life data.
Intracranial in-field progression-free survival (IIFPFS)
The primary objective of the study is to estimate the 1-year intracranial in-field progression-free survival (IIFPFS). Based on results from a retrospective analysis conducted on patients treated at our institution, we expect a 1-year IIFPFS of approximately 57%. With a sample size of 50 patients, the 95% confidence interval (CI) for the 1-year IIFPFS is expected to have an approximate width of 27% (i.e. 43.5-70.5%).
Time frame: From the end of radiotherapy through study completion, every three months.
Overall survival (OS)
Defined as the time from the end of radiotherapy to death
Time frame: From the end of radiotherapy through study completion, every three months.
Progression-free survival (PFS)
Defined as the time from the end of radiotherapy to disease progression (either global intracranial or extracranial) or death, whichever occurred first.
Time frame: From the end of radiotherapy through study completion, every three months.
Intracranial out-field progression free survival (IOFPFS)
defined as the time from the end of radiotherapy to intracranial out-field progression
Time frame: From the end of radiotherapy through study completion, every three months.
Overall intracranial progression free survival (OIPFS)
defined as the time from the end of radiotherapy to the global intracranial progression
Time frame: From the end of radiotherapy through study completion, every three months.
Extracranial progression free survival (EPFS)
defined as the time from the end of radiotherapy to the extracranial progression
Time frame: From the end of radiotherapy through study completion, every three months.
Local control (LC)
Defined as the absence of local progression (complete response, partial response, or stable disease) at the last radiological assessment. The LC rate was calculated among evaluable lesions and reported as a proportion with its 95% confidence interval (CI).
Time frame: From the end of radiotherapy through study completion, every three months.
Adverse events
Stereotactic radiotherapy related adverse events according CTCAE V5.0 and data about radionecrosis will be systematically collected allong the follow up (every trhee months)
Time frame: From the end of radiotherapy through study completion, every three months.
Quality of Life data (QoL) - EORTC QLQ BN20
For EORTC QLQ BN20, 20 items will be completed (score 1-4)
Time frame: From the baseline (start of radiotehrapy), to the end of study (12 months), every three months.
Quality of Life data (QoL) - EORTC QLQ C30 questionnaires.
For EORTC QLQ C30, 30 items will be completed (score 1-4).
Time frame: From the baseline (start of radiotehrapy), to the end of study (12 months), every three months.
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Jan 2030, 40 months after the start.
Of 177 non-industry observational studies under Melanoma, half reached primary completion within 178 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 320. This study's planned 40 months is below that.
Counting every sponsor, half of 236 studies reached it within 71 months; a quarter within 35 and three quarters within 248.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
European Institute of Oncology →